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Background
Mother-to-child transmission (MTCT) of HIV-1 provides
a model for studying the role of passively acquired anti-
bodies in preventing infection. We previously hypothe-
sized that broadly neutralizing heterologous antibodies
(NAbs) would protect babies against intrapartum (IP)
transmission. We measured NAb titers against primary
isolates of various clades in sera from pregnant Thai
women, and identified an association between higher tit-
ers of Nabs against a CRF01_AE primary isolate, MBA, and
lower rates of IP transmission. Here, we extended our pre-
vious study using three CRF01_AE strains in a different
Thai population, to confirm the association previously
observed. We also investigated the molecular characteris-
tics of the MBA envelope glycoprotein (Env) that might
explain this association.
Methods
We measured and compared the titers of NAbs against six
primary isolates (3 CRF01_AE and 3 clade B strains) in
sera from 45 transmitting (T) and 45 nontransmitting
(NT) Thai mothers matched for baseline viral load and
duration of zidovudine prophylaxis, the two main inde-
pendent factors associated with MTCT. We cloned and
sequenced the env gene of the three CRF01_AE strains and
compared the neutralization profiles by mothers' sera of
pseudotyped viruses expressing wild type or chimeric Env
proteins.
Results
Among CRF01_AE strains, MBA was more resistant to
neutralization than the two other strains, LEA and C1712.
The three clade B strains displayed similar neutralization
profiles. We did not find an association between NAbs
and MTCT for the three B strains or for LEA and C1712. In
contrast, higher levels of NAbs against MBA were signifi-
cantly associated with lower rates of IP transmission. The
Env of this strain showed an unusually long V2 domain of
63 amino acids including six potential N-linked glycosyla-
tion sites. Using pseudotyped viruses expressing either
MBA or LEA wild-type Env or a chimeric Env containing
the V2 domain of MBA in an LEA Env backbone, we
showed that the extended V2 domain contributed to the
higher level of resistance to neutralization by mothers'
sera in this strain.
Conclusion
This study confirms that higher titers of maternal NAbs
against a CRF01_AE primary isolate, MBA, are associated
with a lower IP risk of HIV-1 transmission in Thailand,
and that the V2 domain of gp120 seems to have a major
role in the neutralization process. We suggest that some
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primary isolates may be useful indicators for identifying
protective antibodies.Page 2 of 2
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